Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.30 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12674314 | 0.84 | GRM5 (0.31) | GRM5 | |
| SCHEMBL19538589 | 0.80 | HCAR3 (0.34) | HCAR3GRM5GRM1ALDH1A1 | |
| SCHEMBL6840492 | 0.74 | HSD17B10 (0.43) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL19287187 | 0.72 | CYP1A2 (0.38) | HCAR3GRM5GRM1ALDH1A1HPGD | |
| SCHEMBL11964576 | 0.71 | KDM1A (0.41) | ALDH1A1 | |
| SCHEMBL13044094 | 0.70 | ATAD2 (0.41) | MAPK1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL12840678 | 0.70 | KMT2A (0.34) | HCAR3GRM5GRM1ALDH1A1HPGD | |
| SCHEMBL9927079 | 0.69 | CTSK (0.44) | HPGD | |
| SCHEMBL14099757 | 0.69 | L3MBTL1 (0.44) | MAPK1TYRCCNA2CDK2 | |
| SCHEMBL18739478 | 0.68 | KMT2A (0.33) | HCAR3GRM5GRM1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822147-B2 | Methods of treating ophthalmic diseases using NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-13 | — | — | US | disclosed |
| US-9376440-B2 | Pyrrolobenzodiazepines as antiproliferative agents | MEDIMMUNE LIMITED (GB) | 2016-06-28 | — | — | US | disclosed |
| US-20150133435-A1 | PYRROLOBENZODIAZEPINES | MEDIMMUNE LIMITED (GB) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | HCAR3 121/4885MAPK1 1766/4885GRM5 609/4885 |
| US-20150133435-A1 | PYRROLOBENZODIAZEPINES | MBD2, DDB1, PDCD1 | HCAR3 2037/4885MAPK1 3035/4885GRM5 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.